Appropriate use recommendations in search of reimbursement: lecanemab and the UK dilemma

Mummery et al 1 outline the recommendations for the appropriate use (AURs) of the amyloid-targeting monoclonal antibody lecanemab in clinical practice in the United Kingdom. These recommendations are published more than a year after the UK Medicines and Healthcare products Regulatory Agency’s (MHRA) regulatory approval in August 2024.